InterventionsHuman trial

Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin

ADA Scientific Sessions 2026 Abstract

The paper

WELCH MD, FORST TA, JIA W et al.

ADA Scientific Sessions 2026 Abstract · 7 Jun 2026

Presented at ADA Scientific Sessions 2026 · Oral 1254-OR

doi.org/10.2337/db26-1254-or

Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026